MARKET

FLXN

FLXN

Flexion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.39
-0.11
-0.67%
Opening 10:01 11/21 EST
OPEN
16.56
PREV CLOSE
16.50
HIGH
16.56
LOW
16.29
VOLUME
21.33K
TURNOVER
--
52 WEEK HIGH
17.82
52 WEEK LOW
8.76
MARKET CAP
625.68M
P/E (TTM)
-3.9708
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FLXN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

FLXN News

  • Edited Transcript of FLXN earnings conference call or presentation 7-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.4d ago
  • Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings
  • GlobeNewswire.11/11 12:30
  • Flexion Therapeutics Inc (FLXN) Q3 2019 Earnings Call Transcript
  • MotleyFool.com.11/11 05:00
  • Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/10 13:43

More

Industry

Biotechnology & Medical Research
-0.09%
Pharmaceuticals & Medical Research
-0.13%

Hot Stocks

Name
Price
%Change

About FLXN

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
More

Webull offers Flexion Therapeutics Inc (FLXN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.